Chemistry - EG residues

Ethylene glycol contamination from unexpected sources creates toxicity risks - antifreeze exposure, polyester manufacturing residues, or sterilization system leaks introduce this nephrotoxic compound requiring sensitive detection and quantification. Ethylene glycol residue testing addresses contamination from antifreeze exposure during equipment maintenance, polyester manufacturing where glycol represents polymerization residue, or sterilization processes where system leaks introduce this toxic compound. GC-FID quantification following ISO 10993-7 and 10993-12 extraction provides reliable measurement of this toxic compound that causes renal failure through metabolic conversion to oxalic acid. Critical for PET-based devices where residual glycol indicates incomplete polymerization compromising material properties and introducing toxicity, hemodialysis components with direct blood contact where glycol exposure causes severe systemic toxicity, and validating cleaning after equipment maintenance with glycol-containing fluids preventing cross-contamination to products. For polyethylene terephthalate medical devices, ethylene glycol serves as the diol component in polymerization with residual monomer indicating inadequate reaction completion or material degradation. The testing becomes essential when investigating unexpected cytotoxicity potentially caused by glycol contamination, validating new material suppliers ensuring manufacturing processes achieve complete polymerization, or qualifying alternative sterilization methods where some techniques use glycol-based systems. Manufacturing validation confirms processing adequately removes or reacts residual glycol, storage doesn't cause material degradation releasing glycol from polymer chains, and cleaning procedures eliminate glycol from equipment before product processing.

No.
100704
Method
Ethylene glycol by GC-FID after extraction
Industry category
Analyses category
Sample type
Finished device, Bulk material, Liquid sample
Sample requirement (type)
Sterile or non sterile
Sample quantities
1 product, 5 ml
Equipment
GC-FID
Lead Time Standard (Days)
10
Lead Time Express (Days)
5
Lead Time Super Express (Days)
3
Accredited
Yes
Test facility
In House
Add this test to cart to request an offer.

Do you need some help?

Other similar tests

ISO 10993-12, ISO 10993-18, USP 467
IPA residual solvant testing

Manufacturing processes rely heavily on organic solvents for cleaning, extraction, and material processing - yet residual solvents left on medical devices cause cytotoxicity, tissue irritation, and systemic toxicity that threaten patient safety while compromising regulatory compliance. Isopropyl alcohol (IPA) serves as one of the most common solvents in medical device manufacturing, used for cleaning assembled devices, dissolving adhesives, and facilitating material processing, making residual IPA testing fundamental to safety validation. IPA residual solvent analysis following ISO 10993-12 and ISO 10993-18 employs extraction in DMF (dimethylformamide) followed by quantitative GC-FID analysis, providing sensitive detection of residual IPA that could cause adverse biological responses through direct tissue contact or systemic absorption. The extraction methodology ensures complete IPA recovery from device surfaces and absorbed within materials, while GC-FID quantification delivers precise measurement enabling comparison against established safety limits derived from toxicological data and pharmacopeial standards. Critical for validating manufacturing cleaning processes demonstrating adequate IPA removal after solvent-based operations, supporting biocompatibility assessment per ISO 10993-1 where residual solvents contribute to extractables profiles, and ensuring compliance with ICH Q3C guidelines limiting residual solvents in medical devices and pharmaceutical products. For implantable devices and blood-contacting applications, even trace IPA residues pose risks through chronic exposure or direct systemic introduction, requiring validated analytical methods proving residual levels remain below acceptable limits throughout shelf life. The GC-FID approach provides solvent-specific quantification distinguishing IPA from other volatile compounds, supports process validation demonstrating consistent solvent removal across manufacturing lots, and enables investigation of unexpected cytotoxicity potentially linked to inadequate solvent removal. Manufacturing quality control uses IPA testing for batch release decisions ensuring products meet residual solvent specifications, validates that drying or aeration processes adequately remove IPA, and demonstrates that sterilization doesn't trap solvents within sealed packages.